BPC Genesis Fund I SPV Limited and its Person Acting in Concert (PAC), BPC Genesis Fund I-A SPV Limited, have completely exited their positions in Indegene Ltd by selling a combined total of 21,052,478 equity shares on August 6, 2026. The coordinated open market sales on the National Stock Exchange of India Limited (NSE) reduced the group’s aggregate holding from 8.743% of the total voting capital to zero. This complete divestment marks a significant shift in the shareholder structure for the Bengaluru-based healthcare technology company, removing a major institutional block from its public float.

The disclosures were filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on August 7, 2026. Both filings confirm that neither BPC Genesis Fund I SPV Limited nor BPC Genesis Fund I-A SPV Limited holds any interest in Indegene Ltd post-transaction. The transactions were authorized by Mark F. Dzialga, Managing Member of the respective SPVs, acting through Brighton Park Capital Fund I GP, L.P., and Brighton Park Capital Fund I UGP, L.L.C.

Transaction Details

The sales involved only shares carrying voting rights, with no warrants, convertible securities, or encumbered shares involved. Prior to the sales, BPC Genesis Fund I SPV held 13,862,223 shares (5.757% voting capital), while BPC Genesis Fund I-A SPV held 7,190,255 shares (2.986% voting capital). Post-transaction, both entities report zero holdings across all categories.

Capital Structure Context

The total equity share capital of Indegene Ltd remained unchanged at 240,807,964 equity shares following the transactions, based on the shareholding pattern for the quarter ended March 31, 2026. The total diluted share/voting capital stands at 241,466,564 equity shares. Neither seller is part of the promoter or promoter group of the target company.

What the Numbers Show

The simultaneous complete divestment by both BPC Genesis entities indicates a full realization of their investment strategy in Indegene Ltd. With the combined stake dropping from 8.743% to zero, the Brighton Park Capital group has removed itself entirely from the company’s substantial shareholder list. The open market nature of the sales suggests a liquidity event rather than a strategic transfer or off-market deal, impacting the public float dynamics slightly but leaving the promoter group’s control unaffected.

Indegene Limited reported consolidated revenue of ₹10,631 million ($112.5 million) for Q1FY27, a 39.7% year-on-year increase, while management reaffirmed its target to restore EBITDA margins to the historical 19–20% range by Q4FY27. The company’s active client base expanded to 105, with profit after tax (PAT) surging 45.9% sequentially to ₹1,162 million. This performance underscores strong operational leverage despite near-term margin pressure from strategic investments in go-to-market capabilities and large-scale Gen AI engagements.

The Board of Directors approved the unaudited financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells, the statutory auditor, issued an unmodified opinion on the interim financial information. During the subsequent earnings conference call on July 31, 2026, Chairman and CEO Manish Gupta and CFO Suhas Prabhu detailed the drivers behind the sequential growth and clarified the timeline for margin normalization.

Financial Performance

Indegene’s top-line growth was broad-based, with USD revenue rising 26.5% year-on-year. While net profit remained flat year-on-year at ₹1,162 million compared to ₹1,164 million in Q1FY25, it significantly outperformed the previous quarter’s ₹797 million. Employee benefits expense increased to ₹6,591 million from ₹4,815 million in Q1FY25, reflecting investments in headcount and compensation. Other income rose to ₹52 million from a loss of ₹17 million in the prior year period.

Margin Trajectory and Strategic Investments

Management attributed the sequential decline in adjusted EBITDA margins to two primary factors: one-time costs associated with workforce transformation and the initial cost carry of contracted Gen AI engagements under the Tectonic platform. Suhas Prabhu noted that these investments are expected to yield long-term efficiency gains. The company has adopted designated hedge accounting for forward contracts, which will mitigate the impact of forex volatility on reported margins going forward, although undesignated hedges remain material until December 2026.

What the Numbers Show

While revenue expanded by nearly 40% year-on-year, net profit remained flat against the prior year due to higher operating expenses, particularly employee benefits which rose by 36.9%. However, the 45.9% sequential jump in PAT indicates improving efficiency. The divergence between flat YoY PAT and robust revenue growth suggests that recent investments in talent and technology are currently absorbing margins, but the sequential improvement in EBITDA and PAT points to emerging operational leverage as the client base scales beyond the 100-active-client milestone. Management projects that revenue recognition from a major outcome-based omnichannel deal will begin in Q3FY27, with costs already incurred, thereby flowing directly to the bottom line and aiding margin recovery.

Client Concentration and Geography

Revenue concentration decreased slightly, with the top client contributing 9.0% of revenue compared to 12.4% in Q1FY25. The top five clients accounted for 30.4% of revenue, down from 37.9% in the same period last year. Geographically, North America remained the largest market, contributing 75.1% of revenue, followed by Europe at 22.2%. India contributed 0.5%, while the rest of the world accounted for 2.2%. The company’s Days Sales Outstanding (DSO) improved to 67 days from 71 days in Q1FY25, indicating better collection efficiency despite sequential growth.

Strategic Initiatives

Indegene highlighted its focus on GenAI offerings, noting that several solutions have moved from concept to revenue-generating engagements. The company aims to scale these capabilities through FY27, leveraging its homegrown platforms like the NEXT Unified Data Platform. With 29.0% of its delivery team possessing healthcare domain expertise, Indegene positions itself as an embedded revenue partner rather than a traditional IT service provider, aiming to capture higher-value work in commercial and medical activities.